I wonder how prominently (if at all?) PARS will be featured in this special. I doubt they will be mentioned more than one time, but I'd be satisfied with that. Any kind of publicity should do this stock some good.
EDIT: For what it's worth, this Powerpoint Presentation
was made in December of '08. It states that the IIb trial began in June 2007 and that it would last for 12 weeks.
Wouldn't it have been long-since completed? I mean I know they probably take some time to interpret the results, form conclusions, etc... But these numbers show that the experimental phase of the Trial should have been completed by early October '08 at the latest.
The presentation does go on to state that the expected completion time for the study is Late 2009, though. And then, at the end, they say to watch for top line results from the trial in "H1 2010!"
They do, however, say to be aware of the possibility of potential licensings or collaborations with both Dextofisopam and the CB2 Program, which seems to be what the special tomorrow will be about. They don't reveal much about the CB2 Program besides what it is and what it does... no timetable.